Skip to content
Search

Latest Stories

LloydsPharmacy turnover drops 8.5 percent in 2019 fiscal

LloydsPharmacy termed 2018-19 as “another exceptionally challenging period,” after reporting an 8.5 percent decrease in turnover.

In the financial statements for the year ending March 31, 2019, filed recently at the Companies House, the pharmacy chain blamed the pharmacy funding cuts in England for increasing the competition like never before.


"The aggressive targeting of patient by mail order pharmacies means that we have to strive ever harder in order to retain patients and customers,” the report added.

LloydsPharmacy saw a year-over-year turnover decrease of 8.5 per cent to £1.97 billion, which the company attributes to the reduction of pharmacy store portfolio as announced in the prior fiscal year.

Gross profit as percentage of turnover decreased 1.6 per cent compared to the previous year due to the “reductions in pharmacy remunerations and reimbursements.”

“We have seen some loss of market share as a result of further closures and disposals, but market share of the remaining pharmacies has been maintained through a focus of providing relevant and competitive services in our local and national markets,” the report said.

Commenting on the financial report, a McKesson UK spokesperson told Pharmacy Business that the company had to make appropriate commercial decisions because of the increasing financial pressures.

"Good business practice requires us to regularly review our estate and make appropriate commercial decisions including buying and selling pharmacies. We need to operate our stores profitably whilst ensuring patient safety and colleague wellbeing and where we believe this isn’t possible, we may decide to close a pharmacy rather than put these factors at risk," the company spokesperson said.

"These decisions need to be made because of increasing financial pressures, including business rates and changes to pharmacy funding."

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less